Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Failed To Act Against Ketek Clinical Investigator, FDA Charges

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis tells “The Pink Sheet” DAILY that it has cooperated with FDA on the investigation and will respond to the agency warning letter within 15 days.

You may also be interested in...



House Subpoenas FDA Staffers In Ketek Investigation

Von Eschenbach’s congressional briefing documents also subpoenaed as panel delves into when FDA and Sanofi-Aventis became aware of flawed safety study.

House Subpoenas FDA Staffers In Ketek Investigation

Von Eschenbach’s congressional briefing documents also subpoenaed as panel delves into when FDA and Sanofi-Aventis became aware of flawed safety study.

House Panel May Subpoena FDA Investigators To Address Ketek Safety Study

Agency foot-dragging over questions regarding approval of the Sanofi-Aventis antibiotic leads House Energy and Commerce subcommittee to consider forcing testimony.

Topics

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel